Viking Therapeutics Inc (NASDAQ:VKTX) shares are trading higher Tuesday after the company presented new data from its Phase 2b study of VK2809.
What To Know: Viking Therapeutics said its novel liver-selective thyroid hormone receptor beta agonist VK2809 showed statistically significant reductions in liver fat content from baseline to week 12 as compared with placebo.
Viking also said newly reported findings demonstrated robust liver fat reductions among patients with or without type 2 diabetes, as well as patients with either F2 or F3 fibrosis, which shows that VK2809’s potential therapeutic activity is not meaningfully impacted by the presence of type 2 diabetes or fibrosis.
“As steatosis and lipotoxicity are believed to be underlying drivers in NASH, these data suggest benefits across important disease subgroups. We look forward to reporting 52-week biopsy data from VOYAGE in the first half of 2024,” said Brian Lian, CEO of Viking Therapeutics.
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders.
See Also: Why Aviation Leasing Firm AerCap’s Shares Are Falling Today
VKTX Price Action: Viking shares were up 7.96% at $10.72 at the time of publication, according to Benzinga Pro.
Photo: 3844328 from Pixabay.
